127 related articles for article (PubMed ID: 27778096)
21. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.
Kurasawa T; Nagasawa H; Kishimoto M; Amano K; Takeuchi T; Kameda H
Mod Rheumatol; 2014 Jul; 24(4):561-6. PubMed ID: 24252035
[TBL] [Abstract][Full Text] [Related]
22. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
Kojima T; Yabe Y; Kaneko A; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Asai S; Hirabara S; Asai N; Hirano Y; Hayashi M; Miyake H; Kojima M; Ishiguro N
Rheumatology (Oxford); 2015 Jan; 54(1):113-20. PubMed ID: 25102861
[TBL] [Abstract][Full Text] [Related]
23. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
24. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
[TBL] [Abstract][Full Text] [Related]
25. High serum level of haptoglobin is associated with the response of 12 weeks methotrexate therapy in recent-onset rheumatoid arthritis patients.
Tan W; Wang F; Guo D; Ke Y; Shen Y; Lv C; Zhang M
Int J Rheum Dis; 2016 May; 19(5):482-9. PubMed ID: 24863583
[TBL] [Abstract][Full Text] [Related]
26. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
[TBL] [Abstract][Full Text] [Related]
27. Baseline adenosine receptor mRNA expression in blood as predictor of response to methotrexate therapy in patients with rheumatoid arthritis.
Singh A; Misra R; Aggarwal A
Rheumatol Int; 2019 Aug; 39(8):1431-1438. PubMed ID: 31203399
[TBL] [Abstract][Full Text] [Related]
28. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
l'Ami MJ; Kneepkens EL; Nurmohamed MT; Krieckaert CLM; Visman IM; Wolbink GJ
Clin Exp Rheumatol; 2017; 35(3):431-437. PubMed ID: 28079512
[TBL] [Abstract][Full Text] [Related]
29. Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis.
Dhir V; Singla M; Gupta N; Goyal P; Sagar V; Sharma A; Khanna S; Singh S
Clin Ther; 2014 Jul; 36(7):1005-15. PubMed ID: 24976447
[TBL] [Abstract][Full Text] [Related]
30. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
[TBL] [Abstract][Full Text] [Related]
31. The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.
Soukup T; Dosedel M; Pavek P; Nekvindova J; Barvik I; Bubancova I; Bradna P; Kubena AA; Carazo AF; Veleta T; Vlcek J
Rheumatol Int; 2015 Jul; 35(7):1149-61. PubMed ID: 25618758
[TBL] [Abstract][Full Text] [Related]
32. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
33. Serum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: Results from the SWEFOT Trial.
Hambardzumyan K; Bolce RJ; Wallman JK; van Vollenhoven RF; Saevarsdottir S
J Rheumatol; 2019 Jun; 46(6):555-563. PubMed ID: 30709958
[TBL] [Abstract][Full Text] [Related]
34. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
Bakker MF; Jacobs JW; Welsing PM; Verstappen SM; Tekstra J; Ton E; Geurts MA; van der Werf JH; van Albada-Kuipers GA; Jahangier-de Veen ZN; van der Veen MJ; Verhoef CM; Lafeber FP; Bijlsma JW;
Ann Intern Med; 2012 Mar; 156(5):329-39. PubMed ID: 22393128
[TBL] [Abstract][Full Text] [Related]
35. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).
Verstappen SM; Jacobs JW; van der Veen MJ; Heurkens AH; Schenk Y; ter Borg EJ; Blaauw AA; Bijlsma JW;
Ann Rheum Dis; 2007 Nov; 66(11):1443-9. PubMed ID: 17519278
[TBL] [Abstract][Full Text] [Related]
36. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
Keystone EC; Haraoui B; Guérette B; Mozaffarian N; Liu S; Kavanaugh A
J Rheumatol; 2014 Feb; 41(2):235-43. PubMed ID: 24293583
[TBL] [Abstract][Full Text] [Related]
37. MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy.
Shiozawa K; Yamane T; Murata M; Yoshihara R; Tsumiyama K; Imura S; Shiozawa S
Arthritis Res Ther; 2016 Feb; 18():55. PubMed ID: 26922083
[TBL] [Abstract][Full Text] [Related]
38. Suboptimal methotrexate use in rheumatoid arthritis patients in Italy: the MARI study.
Idolazzi L; Adami S; Capozza R; Bianchi G; Cozzolongo A; Epis O; Fusaro E; Lapadula G; Migliore A; Pellerito R; Pucino A; Sinigaglia L; Visalli E; Rossini M
Clin Exp Rheumatol; 2015; 33(6):895-9. PubMed ID: 26690890
[TBL] [Abstract][Full Text] [Related]
39. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.
Proudman SM; James MJ; Spargo LD; Metcalf RG; Sullivan TR; Rischmueller M; Flabouris K; Wechalekar MD; Lee AT; Cleland LG
Ann Rheum Dis; 2015 Jan; 74(1):89-95. PubMed ID: 24081439
[TBL] [Abstract][Full Text] [Related]
40. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
